Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 23-valent pneumococcal polysaccharide vaccine in healthy participants aged 2 years and older
ChiCTR2000030009Phase 3Completed
- Sponsor
- Guangxi Center for Disease Control and Prevention
- Start
- Jul 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (3 arms), sponsored by Guangxi Center for Disease Control and Prevention. Primary endpoint: Immunogenicity. Started Jul 2015; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ChiCTR2000030009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030009.